Eli Lilly Aktie 947556 / US5324571083
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
03.11.2025 15:11:08
|
Eli Lilly To Build New $3 Bln Manufacturing Facility To Boost Oral Medicine Production Capacity
(RTTNews) - Eli Lilly and Co. (LLY) announced Monday plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This facility will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.
The proposed facility will also bring 500 high-wage manufacturing jobs to the South Holland province, including highly skilled engineers, scientists, operations personnel and lab technicians. It will also bring an estimated 1,500 construction jobs.
The construction of the facility is expected to begin next year. Lilly's investment is contingent upon the finalization of government permits and local approvals.
The facility will incorporate advanced manufacturing technologies to meet the needs of Lilly's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology.
The innovative capabilities will include dock-to-dock automation and material flow, paperless manufacturing, process analytical technology and spray-dried dispersion, which allows oral medicines to be effectively absorbed.
The new site will also be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist. The company expects to submit orforglipron to global regulatory agencies for obesity by the end of this year.
Lilly has established a strong manufacturing footprint in Europe with four existing sites across France, Ireland, Italy and Spain.
To meet the growing demand for Lilly medicines, the company has shared plans for three additional EU sites since 2020, including new greenfield sites in Ireland, Germany, and now, the Netherlands.
Lilly's ongoing investments in Europe will create operational synergies and supply chain flexibility, support the early-stage life science ecosystem and strengthen university and government relationships.
Nachrichten zu Eli Lilly
Analysen zu Eli Lilly
| 20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Mut zur Börse: Lohnt sich die wertschriftengebundene Säule 3a wirklich?
💡 Mut zur Börse in der Vorsorge!
Im Gespräch mit Versicherungsexperte Christian Jetzer geht es um die wohl spannendste Frage der privaten Altersvorsorge:
👉 Lohnt sich die wertschriftengebundene Säule 3a wirklich?
Viele Schweizerinnen und Schweizer sparen weiterhin auf dem klassischen 3a-Sparkonto – trotz minimaler Zinsen und hoher Inflation. Christian Jetzer erklärt, warum Anlegen mit Wertschriften heute fast ein Muss ist, welche Renditechancen und Risiken bestehen und wie du Steuern sparen kannst.
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Eli Lilly am 03.11.2025
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
US-Börsen letztlich leichter -- SMI beendet Handel im Plus -- DAX schliesst schwächer -- Asiens Börsen letztlich in RotDer heimische Aktienmarkt konnte sich am Dienstag im Handelsverlauf ins Plus vorarbeiten. Der deutsche Markt gab im Dienstagshandel derweil nach. An der Wall Street kam es zu Verlusten. An den asiatischen Aktienmärkten ging es am Dienstag abwärts.


